Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $24.69 and traded as low as $17.66. Arcturus Therapeutics shares last traded at $17.73, with a volume of 330,986 shares traded.
Analysts Set New Price Targets
Several brokerages recently commented on ARCT. Leerink Partners initiated coverage on shares of Arcturus Therapeutics in a research note on Monday, August 12th. They issued an "outperform" rating and a $70.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a report on Tuesday, October 1st. Leerink Partnrs raised Arcturus Therapeutics to a "strong-buy" rating in a research note on Monday, August 12th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $71.40.
Check Out Our Latest Stock Analysis on Arcturus Therapeutics
Arcturus Therapeutics Price Performance
The company has a market cap of $484.74 million, a PE ratio of -7.06 and a beta of 2.61. The firm has a 50-day simple moving average of $20.94 and a two-hundred day simple moving average of $24.64.
Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($1.85) by $1.21. The firm had revenue of $49.86 million during the quarter, compared to analysts' expectations of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same quarter last year, the business posted ($1.98) EPS. Equities research analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.6 EPS for the current year.
Insider Activity
In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of Arcturus Therapeutics stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares of the company's stock, valued at approximately $9,037,533.84. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 15.30% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. raised its stake in shares of Arcturus Therapeutics by 148.0% in the 1st quarter. Principal Financial Group Inc. now owns 17,516 shares of the biotechnology company's stock valued at $592,000 after acquiring an additional 10,454 shares during the period. Nordea Investment Management AB acquired a new position in Arcturus Therapeutics in the first quarter valued at approximately $1,846,000. Russell Investments Group Ltd. acquired a new position in Arcturus Therapeutics during the 1st quarter valued at approximately $40,000. ProShare Advisors LLC bought a new position in shares of Arcturus Therapeutics during the first quarter worth about $205,000. Finally, State Board of Administration of Florida Retirement System grew its position in Arcturus Therapeutics by 32.3% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,841 shares of the biotechnology company's stock worth $299,000 after purchasing an additional 2,160 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company's stock.
Arcturus Therapeutics Company Profile
(
Get Free Report)
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Featured Stories
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
